Mesenchymal stem cell-derived extracellular vesicles alleviate autism by regulating microglial glucose metabolism reprogramming and neuroinflammation through PD-1/PD-L1 interaction.

Bibliographic Details
Title:	Mesenchymal stem cell-derived extracellular vesicles alleviate autism by regulating microglial glucose metabolism reprogramming and neuroinflammation through PD-1/PD-L1 interaction.
Authors:	Qin, Qian¹ (AUTHOR), Fan, Linlin¹ (AUTHOR), Zeng, Xin¹ (AUTHOR), Zheng, Danyang¹ (AUTHOR), Wang, Han¹ (AUTHOR), Li, Mengyue¹ (AUTHOR), Jiang, Yutong¹ (AUTHOR), Wang, Hui¹ (AUTHOR), Liu, Hao¹ (AUTHOR), Liang, Shengjun¹ (AUTHOR), Wu, Lijie¹ (AUTHOR) wulijiehyd@126.com, Liang, Shuang¹ (AUTHOR) liangyouyou2004@163.com
Source:	Journal of Nanobiotechnology. 3/11/2025, Vol. 23 Issue 1, p1-25. 25p.
Subject Terms:	MATERNAL immune activation, METABOLIC reprogramming, IMMUNE checkpoint proteins, AUTISM spectrum disorders, *INTRANASAL administration
Abstract:	Neuroinflammation triggered by microglia activation is hallmark of autism spectrum disorder (ASD), and this process includes crucial metabolic reprogramming from oxidative phosphorylation to glycolysis, which may cause neuron loss and functional impairment. The inhibitory immune checkpoint programmed cell death protein 1 (PD-1) on immune cells is an important target for tumor immunotherapy. However, the immunomodulatory effects of PD-1 in ASD remains to be elusive. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) exhibit immunomodulatory capabilities in a range of neurological diseases. Our findings indicated the expression of PD-L1 on MSC-EVs, potentially facilitating signaling to PD-1-expressing microglia. Here, we showed how MSC-EVs activated of PD-L1/PD-1 axis and ameliorated glycolysis, neuroinflammation and autism-like behaviors. After first detecting elevated glycolysis and neuroinflammation in prefrontal cortex (PFC) tissue from the maternal immune activation (MIA) mice, we also demonstrated that PD-1 expression level was upregulated in microglia. Following given MSC-EVs carried PD-L1 into adult MIA offspring mice via intranasal administration, which bound with PD-1 on microglia and then the autism-like behaviors were alleviated as well. Further experiments verified that MSC-EVs could decreased the level of glycolysis and neuroinflammation by PD-1/ERK/HIF-1α pathway in the primary microglia in PFC of MIA offspring mice. Pharmacological blockade and genetic inhibition of PD-1 could weaken the effect of MSC-EVs and aggravate microglial dysfunction, glycolysis and autism-like behaviors in MIA offspring mice. Futhermore, PD-L1 deficient weakened the effect of MSC-EVs on neuroinflammation, glycolysis and autism-like behaviors in MIA offspring mice. Our research indicated the significant immunomodulatory capabilities of MSC-EVs, which play an important role in reprogramming microglial glucose metabolism and suppressing neuroinflammation in ASD. By activating the PD-L1/PD-1 axis and inhibiting the downstream ERK/HIF-1α pathway, MSC-EVs were found to alleviate autism-like behaviors, which revealing a novel pathological mechanism and offering promising therapeutic insights into ASD. [ABSTRACT FROM AUTHOR]
	Copyright of Journal of Nanobiotechnology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Academic Search Complete
Full text is not displayed to guests.	Login for full access.

More Details
ISSN:	14773155
DOI:	10.1186/s12951-025-03250-z
Published in:	Journal of Nanobiotechnology
Language:	English